Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems

Table 3

Polymeric nanoparticles used as EGCG carriers. Note. N/A denotes “not available” data.

Particle	Loading capacity (%)	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.
Chitosan	0.4	N/A	440 ± 37	Oral	Enhancement of the gastrointestinal permeation of EGCG in mice.	[37, 38]
Chitosan, casein, and peptides	N/A	N/A	150	Oral	Bioavailability of EGCG increment in Caco-2 monolayers.	[39]
Chitosan casein phosphopeptides	N/A	N/A	150 ± 4.3	Oral	Enhancement of the intestinal permeation of EGCG using Caco-2 monolayers.	[40]
Chitosan and aspartic acid	N/A	25	102	Oral	Increased antiatherosclerotic activity in rabbits.	[41]
Chitosan	N/A	~10	~150	Oral	Reduction of human prostate tumors in mice.	[42]
Chitosan tripolyphosphate (CS/TPP)	N/A	40–90	143–450	N/A	Inhibition of MCF-7 breast cancer cells proliferation. Higher levels of modulation of PI3K-Akt pathway.	[43]
PLGA and PEG	~0,4	~9,5	80 ± 15.0	Intravenous	Inhibition of the growth of cultured cancerous cells.	[44]
PLA PEG	N/A	N/A	N/A	Intravenous	Reduction in the size of the implanted tumor in mice.	[45]
PLGA and PEG	1.94–2.21	49–55	130–250	Intravenous	Accentuated antiproliferative effect on 3 different prostate cancer cell types. Significant inhibition of prostate tumor growth in vivo.	[46]
PLGA	5.76	26	127	Topical	Inhibition of DNA damage.	[47]
Ovalbumin-dextran	20.9	30.0	339	Oral	Enhancement of the intestinal stability and improvement of apparent permeability in Caco-2 models.	[48]